TB-500 (Thymosin Beta-4 Fragment) and ALS (Amyotrophic Lateral Sclerosis): Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

TB-500 (Thymosin Beta-4 Fragment) and ALS (Amyotrophic Lateral Sclerosis): Latest Research 2026

This page summarizes the current state of scientific research on TB-500 (Thymosin Beta-4 Fragment) in the context of ALS (Amyotrophic Lateral Sclerosis) as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your neurologist or ALS specialist for personalized guidance.

Compound Overview

TB-500 (Thymosin Beta-4 Fragment) (Peptide / Regenerative) — Research compound; not FDA-approved for any indication

Mechanism of action: Actin sequestration and cell migration promotion; angiogenesis; anti-inflammatory; tissue repair

Current evidence level: Animal studies only; no peer-reviewed human clinical trials

2026 Research Landscape

Research has directly examined TB-500 (Thymosin Beta-4 Fragment) in ALS, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how TB-500 (Thymosin Beta-4 Fragment) affects the biological pathways involved in ALS (Amyotrophic Lateral Sclerosis) progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining TB-500 (Thymosin Beta-4 Fragment) in ALS patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(TB-500 (Thymosin Beta-4 Fragment)[tiab]) AND (ALS (Amyotrophic Lateral Sclerosis)[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with TB-500 (Thymosin Beta-4 Fragment) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the TB-500 (Thymosin Beta-4 Fragment) + ALS research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in ALS patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on TB-500 (Thymosin Beta-4 Fragment) for ALS?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'TB-500 (Thymosin Beta-4 Fragment) ALS (Amyotrophic Lateral Sclerosis)' filtered to the last 2 years. The current evidence level is: Animal studies only; no peer-reviewed human clinical trials.

Are there any 2025-2026 clinical trials for TB-500 (Thymosin Beta-4 Fragment) in ALS?

Check ClinicalTrials.gov with 'TB-500 (Thymosin Beta-4 Fragment)' as intervention and 'ALS (Amyotrophic Lateral Sclerosis)' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your neurologist or ALS specialist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for TB-500 (Thymosin Beta-4 Fragment) in ALS changed recently?

The field evolves rapidly. The current evidence classification is: Animal studies only; no peer-reviewed human clinical trials. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.